Animal Model Market to Hit $5.4B by 2033, 9.6% CAGR

The Animal Model Market Report is poised for robust expansion, with the global Animal Model Market projected to grow from $2.6 billion in 2025 to $5.4 billion by 2033, registering a CAGR of 9.6%. This growth is fueled by escalating R&D expenditure in oncology and immunology, advancements in genetic engineering, and increasing demand for humanized models.

• North America dominates with a 35% share in 2025, underpinned by major players like Charles River Laboratories and The Jackson Laboratory.
• Asia-Pacific is the fastest-growing region, expected to expand at 11.5% CAGR, driven by CRO expansion and government funding.
• The Mice Model Market accounts for the largest share at 45% of total revenue, due to their genetic similarity to humans and ease of modification.
• Cancer research remains the leading application, representing 40% of demand, as pharmaceutical companies intensify oncology pipelines.

Key challenges include stringent regulations and ethical concerns, which are driving investment in alternative methods. However, the market's trajectory remains strong, with strategic partnerships and technological breakthroughs expected to create new opportunities.

The Mice Model Market is the cornerstone of the animal model industry, accounting for 45% of global revenue in 2025. Their dominance stems from genetic homology with humans, well-established breeding protocols, and the ability to create transgenic and knockout models. The Cancer Research Animal Model Market heavily utilizes mice, with over 60% of oncology studies relying on mouse models. Growth in this segment is propelled by the rise of immuno-oncology and precision medicine.

• Genetically Modified Animal Model Market: This sub-segment is growing at 12.3% CAGR, driven by CRISPR and other gene-editing technologies.
• Rat Model Market: Valued at $650 million in 2025, rats are preferred for toxicology and cardiovascular research due to their larger size and physiological similarities.
• Immunological Disease Animal Model Market: This application segment is expected to grow at 10.8% CAGR, fueled by autoimmune disease research.

Margin pressures are significant, with maintenance costs accounting for 40% of total costs. Vendors are automating breeding and phenotyping to reduce expenses. The Pharmaceutical Animal Model Market remains the largest end-user, representing 55% of demand, as pharma companies outsource preclinical testing to CROs.

The Animal Model Market is primarily driven by the pharmaceutical industry's increasing focus on precision medicine. Over 70% of new drug candidates require animal testing before human trials, ensuring sustained demand. Government initiatives, such as the NIH's $500 million annual funding for preclinical research, further bolster the market.

However, ethical and regulatory pressures are intensifying. The EU's Directive 2010/63/EU mandates the '3Rs' (replacement, reduction, refinement), pushing researchers toward alternatives. This has led to a 10-15% reduction in animal use for early-stage screening. Nonetheless, for complex diseases like cancer, animal models remain irreplaceable.

• Charles River Laboratories: Dominates with a 30% market share, offering end-to-end preclinical services.
• The Jackson Laboratory: Non-profit powerhouse, provides over 10,000 mouse strains and CRISPR-ready models.
• Taconic Biosciences, Inc.: Specializes in humanized and knockout models, with a strong presence in Europe.
• genOway: Focuses on CRISPR and rat models, serving niche academic and biotech clients.
• Crown Bioscience: Leader in patient-derived xenograft (PDX) models for oncology.
• Inotiv: Provides integrated toxicology and pathology services, recently expanding through acquisitions.
• BIOCYTOGEN: Chinese provider of genetically modified models, growing rapidly in Asia-Pacific.
• Hooke Laboratories: Niche player in experimental autoimmune encephalomyelitis (EAE) models.

• In 2024, Charles River Laboratories acquired a gene-editing firm to integrate CRISPR technology, enhancing its custom model capabilities.
• The Jackson Laboratory partnered with a top-10 pharmaceutical company to create humanized mouse models for immuno-oncology, expected to accelerate drug development.
• Taconic Biosciences launched a novel immunodeficient mouse strain, targeting cancer and infectious disease research, capturing a 5% market share in the segment.
• Crown Bioscience expanded its operations in China, capitalizing on the 11.5% CAGR of the Asia-Pacific Animal Model Market.

North America leads with $0.91 billion in 2025, but its growth is maturing. Europe follows closely, driven by Horizon 2020 funding and stringent ethical standards. The Asia-Pacific Animal Model Market is the fastest-growing, propelled by China's Animal Model Resource Center and India's expanding CRO industry. LAMEA shows promise with increasing preclinical outsourcing, though regulatory frameworks are still developing.

• United States: Dominates North America with 80% share, supported by NIH funding and major vendors.
• China: Expected to grow at 13% CAGR, as local players like BIOCYTOGEN expand.
• Germany: Largest European market, with a focus on genetically modified models.
• Brazil: Emerging hub in Latin America, attracting CRO investments.

The Animal Model Market has witnessed a surge in M&A and investment activity over the past three years. Private equity and venture capital firms have invested over $500 million in animal model startups since 2021, focusing on humanized models and CRISPR technology. Key acquisitions include Charles River Laboratories' purchase of Retrogenix in 2021 for $60 million, enhancing its custom model capabilities.

High-growth sub-segments attracting capital include:

• Genetically Modified Animal Model Market: Expected to reach $1.2 billion by 2030, with 12.3% CAGR.
• Contract Research Organization Animal Model Market: Growing at 10.5% CAGR, as pharma companies outsource preclinical testing.
• Humanized Mice Models: A niche but rapidly expanding segment, with investments from Taconic Biosciences and The Jackson Laboratory.

Strategic partnerships between CROs and pharmaceutical companies have increased by 25% since 2021, aimed at sharing risks and accelerating drug development. This trend is expected to continue, driving consolidation and innovation.

Three disruptive technologies are reshaping the Animal Model Market:

1. CRISPR and Gene Editing: The CRISPR Animal Model Market is growing at 15% CAGR, enabling precise genetic modifications. Adoption is accelerating, with over 50% of new models using CRISPR by 2025.
2. Humanized Models: These models engraft human cells or tissues into mice, improving translational relevance. The Immunological Disease Animal Model Market benefits significantly, with humanized models reducing drug failure rates by 20%.
3. Organ-on-a-Chip: While still emerging, this technology threatens to replace animal models for toxicity testing. However, it currently complements animal studies, and full adoption is expected post-2030.

R&D investment in animal model technologies reached $1.2 billion in 2024, with a focus on automation and AI-driven phenotyping. Patent filings for genetically modified models increased by 30% from 2020 to 2024. Incumbent business models are reinforced by the complexity of human diseases, which require whole-organism systems that organ-on-chip cannot fully replicate.

• 1. Animal Type
  • 1.1. Mice
  • 1.2. Rat
  • 1.3. Guinea Pigs
  • 1.4. Rabbits
  • 1.5. Hamsters
  • 1.6. Others
• 2. Application
  • 2.1. Cancer
  • 2.2. Immunological Disease
  • 2.3. Infectious Disease
  • 2.4. Others
• 3. End-use
  • 3.1. Pharmaceutical & Biotechnology Companies
  • 3.2. Academic Research Institute
  • 3.3. Contract Research Organization

• 1. North America
  • 1.1. United States
  • 1.2. Canada
  • 1.3. Mexico
• 2. South America
  • 2.1. Brazil
  • 2.2. Argentina
  • 2.3. Rest of South America
• 3. Europe
  • 3.1. United Kingdom
  • 3.2. Germany
  • 3.3. France
  • 3.4. Italy
  • 3.5. Spain
  • 3.6. Russia
  • 3.7. Benelux
  • 3.8. Nordics
  • 3.9. Rest of Europe
• 4. Middle East & Africa
  • 4.1. Turkey
  • 4.2. Israel
  • 4.3. GCC
  • 4.4. North Africa
  • 4.5. South Africa
  • 4.6. Rest of Middle East & Africa
• 5. Asia Pacific
  • 5.1. China
  • 5.2. India
  • 5.3. Japan
  • 5.4. South Korea
  • 5.5. ASEAN
  • 5.6. Oceania
  • 5.7. Rest of Asia Pacific